Many pharmaceuticals are produced using Saccharomyces cerevisiae as an expression system. Yeasts used as expression systems are typically heavily genetically modified and as a result, these transformed yeast strains become more fragile. MicroBioGen offers cutting-edge technology to build high levels of industrial robustness into yeast expression systems whilst introducing value added features such as:
- Easy to manipulate and incorporate GM constructs
- Industrial haploid rather than diploid availability
- Super low nutrient requirements
- Enhanced backbone yeast to overexpress foreign proteins
Available for collaboration with or without GM constructs incorporated into the program. Collaborate with us to build high levels of industrial robustness into your yeast expression systems.